ReviewFrontiers in pharmacology2026
Nanotechnology-enabled delivery of luteolin: a comprehensive review on multidisease therapeutic applications.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Luteolin is a natural flavonoid compound widely found in various plants, known for its antioxidant, anti-inflammatory, cardiovascular protective and anti-tumor activities. However, its low bioavailability due to rapid metabolism and low solubility hinders its clinical application. In recent years, with the development of nanotechnology, luteolin combined with nanomaterials to form nanocomposites has shown promising drug delivery performance and therapeutic effects in numerous diseases. This article reviews the latest research progress on luteolin nanocomposites in disease treatment, exploring their potential applications in cancer, diabetes, cardiovascular diseases, neurological disorders, and other conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.